NCT05820802 High Dimensional Analysis of Immune Cells in Pediatric Patients
| NCT ID | NCT05820802 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Drug Allergy |
| Study Type | OBSERVATIONAL |
| Enrollment | 294 participants |
| Start Date | 2023-04-27 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 294 participants in total. It began in 2023-04-27 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.
Eligibility Criteria
Inclusion Criteria: * Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium. Exclusion Criteria: * Patients who have received immunomodulators, immunosuppressants, etc. * Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.) * Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.) * Other cases where the Principal Investigator determines that it is difficult to conduct the study.
Frequently Asked Questions
Who can join the NCT05820802 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 18 Years, studying Drug Allergy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05820802 currently recruiting?
Yes, NCT05820802 is actively recruiting participants. Visit ClinicalTrials.gov or contact Seoul National University Hospital to inquire about joining.
Where is the NCT05820802 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05820802 clinical trial?
NCT05820802 is sponsored by Seoul National University Hospital. The trial plans to enroll 294 participants.